A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma
Open Access
- 20 January 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1), e0170521
- https://doi.org/10.1371/journal.pone.0170521
Abstract
Extensive epidemiological data have demonstrated an exponential rise in the incidence of non-Hodgkin lymphoma (NHL) that is associated with increasing age. The molecular etiology of this remains largely unknown, which impacts the effectiveness of treatment for patients. We proposed that age-dependent circulating microRNA (miRNA) signatures in the host influence diffuse large B cell lymphoma (DLBCL) development. Our objective was to examine tumor development in an age-based DLBCL system using an inventive systems biology approach. We harnessed a novel murine model of spontaneous DLBCL initiation (Smurf2-deficient) at two age groups: 3 and 15 months old. All Smurf2-deficient mice develop visible DLBCL tumor starting at 15 months of age. Total miRNA was isolated from serum, bone marrow and spleen and were collected for all age groups for Smurf2-deficient mice and age-matched wild-type C57BL/6 mice. Using systems biology techniques, we identified a list of 10 circulating miRNAs being regulated in both the spleen and bone marrow that were present in DLBCL forming mice starting at 3 months of age that were not present in the control mice. Furthermore, this miRNA signature was found to occur circulating in the blood and it strongly impacted JUN and MYC oncogenic signaling. In addition, quantification of the miRNA signature was performed via Droplet Digital PCR technology. It was discovered that a key miRNA signature circulates throughout a host prior to the formation of a tumor starting at 3 months old, which becomes further modulated by age and yielded calculation of a ‘carcinogenic risk score’. This novel age-based circulating miRNA signature may potentially be leveraged as a DLBCL risk profile at a young age to predict future lymphoma development or disease progression as well as for potential innovative miRNA-based targeted therapeutic strategies in lymphoma.Funding Information
- National Cancer Institute (R01 CA164311)
This publication has 65 references indexed in Scilit:
- Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphomaBlood Cancer Journal, 2013
- CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico dataBioinformatics, 2013
- MiR-27 as a Prognostic Marker for Breast Cancer Progression and Patient SurvivalPLOS ONE, 2012
- Smurf2 Regulates the Senescence Response and Suppresses Tumorigenesis in MiceCancer Research, 2012
- Reprogramming Tumor-Associated Dendritic Cells In Vivo Using miRNA Mimetics Triggers Protective Immunity against Ovarian CancerCancer Research, 2012
- MicroRNA signatures in B-cell lymphomasBlood Cancer Journal, 2012
- Regulation of let-7 and its target oncogenes (Review)Oncology Letters, 2012
- Epigenetic Down-Regulation of the Tumor Suppressor Gene PRDM1/Blimp-1 in Diffuse Large B Cell Lymphomas: A Potential Role of the MicroRNA Let-7The American Journal of Pathology, 2010
- Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B‐cell lymphoma treated with R‐CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E‐IPI)British Journal of Haematology, 2010
- Regression of murine lung tumors by the let-7 microRNAOncogene, 2009